genome engineering

PRESS RELEASE

Cellectis announces the final completion of the acquisition of Cellartis and €50 million financing round reserved for the FSI and Mr. Pierre Bastid.

Paris, Friday November 4, 2011 - Cellectis (Alternext: ALCLS) announces the final completion of the acquisition of Cellartis, the Swedish company and European market leader for stem cell-based in vitro R&D tools, and the resulting issue of 1,933,333 Cellectis shares to the former Cellartis' shareholders, as well as the final completion of the issue of 6,250,000 convertible bonds for €50 million, evenly subscribed by the French strategic investment fund (FSI) and Mr. Pierre Bastid.

Consequently, the free share purchase warrants granted on November 1st, 2011 to all Cellectis' shareholders (not including the FSI, Mr. Pierre Bastid and Cellartis' shareholders) based on the Euroclear France positions at October 31st, 2011, will be registered for trading on the Alternext market of NYSE Euronext Paris on November 7th, 2011 and may be exercised from the same day until October 28th, 2014.

* * *

For further information, please contact:

Cellectis
Philippe Valachs
Company Secretary
Tel: +33 (0)1 81 69 16 00
media@cellectis.com

Marc Le Bozec
Chief Financial Officer
Tel: +33 (0)1 81 69 16 00
investor@cellectis.com

Calyptus
Alexis Breton / Cyril Combe
Tel: +33 (0)1 53 65 68 68
cellectis@calyptus.net